US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

56.93 +0.08 (+0.14%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Expert Ratings For Travere Therapeutics ↗
 
Via Benzinga
News headline image
Travere Therapeutics Reports Second Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal ↗
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus... 
Via Talk Markets
News headline image
Travere Therapeutics to Report Second Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts ↗
 
Via Benzinga
News headline image
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insights ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (7 Ratings) ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 15, 2024 ↗
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Preview For Travere Therapeutics ↗
 
Via Benzinga
News headline image
TVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024 ↗
TVTX stock results show that Travere Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Travere Therapeutics Reports First Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics to Report First Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
Posters to be presented highlighting research investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria 
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
Upcoming data presentations underscore the potential for FILSPARI to become a foundational treatment for IgAN and Travere’s leadership and commitment to innovation in rare kidney disease (RKD) 
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
Submission is based on 2-year confirmatory results from the Phase 3 PROTECT Study in which FILSPARI demonstrated a significant reduction in proteinuria, preservation of kidney function and a generally... 
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >